Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05335993 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
A Phase 2 study of Peritoneal Cancer and Recurrent Ovarian Cancer, sponsored by CanariaBio.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT05335993 is a Phase 2 study of Peritoneal Cancer and Recurrent Ovarian Cancer that is active but no longer recruiting, run by CanariaBio. The registered enrollment target is 10 participants, below the 154-participant average among 32 other Peritoneal Cancer trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05335993, a Phase 2 study of Peritoneal Cancer and Recurrent Ovarian Cancer, is active but no longer recruiting, sponsored by CanariaBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.
Conditions Studied
Interventions
- DRUG Niraparib
- BIOLOGICAL Oregovomab
Study Locations (3)
North Carolina
- Duke Cancer Center - Durham
Oklahoma
- Stephenson Cancer Center- University of Oklahoma Health Sciences Center - Oklahoma City
Virginia
- University of Virginia Health System - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2025-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05335993
The ClinicalTrials.gov registry entry for NCT05335993 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 32 other Peritoneal Cancer trials with a reported enrollment target (94% lower). The listed sponsor is CanariaBio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Peritoneal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Niraparib is the first listed.
NCT05335993 reports 3 study locations spanning 3 distinct geographic areas - top geographies include North Carolina, Oklahoma, Virginia.
Frequently Asked Questions
What is clinical trial NCT05335993 about?
NCT05335993 is a clinical study titled "A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.". Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.
What is the current status of trial NCT05335993?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-07-25. Estimated completion is 2025-07-30.
What conditions does trial NCT05335993 study?
This clinical trial studies the following conditions: Peritoneal Cancer, Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer.
What interventions are being tested in trial NCT05335993?
The interventions under investigation include: Niraparib (DRUG), Oregovomab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05335993?
This trial is sponsored by CanariaBio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05335993 being conducted?
This trial has 3 study locations across North Carolina, Oklahoma, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peritoneal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
-
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
ACTIVE NOT RECRUITING · Phase 2
-
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.